All type of patients: 42 trials - Buse - Apovian - DeFronzo (EXE vs ROSI) - Derosa - DURATION-2 (Bergenstal) (vs pioglitazone) - DURATION-2 (Bergenstal) (vs sitagliptin) - DURATION-3 (Diamant) - Gill - Liutkus - Bergenstal (once daily) - Bergenstal (twice daily) - Bunck - Gao - HEELA (Davies) - Kadowaki (trial 8683) - LEAD 6 (Buse) exe vs lira - DeFronzo - Drucker - H8O-MC-GWBJ, 9698, 10µg/d - H8O-MC-GWBJ, 9698, 20µg/d - Moretto (DOUBLONS avec druker) - Barnett - Davis - Kim - Nauck - Zinman 20µg/j - Zinman 20µg/j A MODIFIER - DeFronzo 10µg/d - DeFronzo 20µg/d - Heine - Kendall 10µg/d - Kendall 20µg/d - Poon - Buse 10µg/d - Buse 20µg/d - Fineman - H8O-MC-GWDE - Exenatide Trial 10749 - NCT00085969 - NCT00360334 - phase 2 exenatide once monthly - Trial 8078
Patients inadequately controlled on MET+SU therapy : 4 trials - Nauck - Heine - Kendall 10µg/d - Kendall 20µg/d
Patients inadequately controlled on metformin: 4 trials - Gao - Kim - DeFronzo 10µg/d - DeFronzo 20µg/d
Patients inadequately controlled on monotherapy : 9 trials - Gao - Kim - DeFronzo 10µg/d - DeFronzo 20µg/d - Buse 10µg/d - Buse 20µg/d - Fineman - Exenatide Trial 10749 - Trial 8078
Patients inadequately controlled with insulin: 7 trials - Buse - DURATION-3 (Diamant) - Barnett - Davis - Nauck - Heine - Trial 8078
Patients with insufficient glycaemic control with bitherapy: 11 trials - Gao - Kadowaki (trial 8683) - Davis - Nauck - Zinman 20µg/j - Zinman 20µg/j A MODIFIER - Heine - Kendall 10µg/d - Kendall 20µg/d - Fineman - phase 2 exenatide once monthly
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
